- BySeeking Alpha-
Celsion (CLSN): Q1 GAAP EPS of -$0.09.Revenue of $0.13M (flat Y/Y)Press Release
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks(Biotech Stocks Hitting 52-week Highs May 13)Alexion Pharmaceuticals, Inc....
Despite the recent market-wide pullback, oncology drug-maker Celsion (CLSN) is enjoying a breakout year, with shares up by 210% year-to-date. One Street analyst thinks the stock...
Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).